Denmark's Novo Nordisk wants to prove it can transform the diabetes market with a pill.
7 Feb 2018 8:30 AM GMT
The daily pill belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production.
7 Feb 2018 3:12 AM GMT